Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Actavis Says FDA Accepts NDA For Progestin-only Contraceptive Patch

RELATED NEWS
Trade ACT now with 
5/13/2013 9:12 AM ET

Specialty pharmaceutical company Actavis, Inc. (ACT) Monday said the U.S. Food and Drug Administration has accepted for filing its New Drug Application for a progestin-only transdermal contraceptive patch, Norethindrone Transdermal Delivery System, for use by women to prevent pregnancy.

The acceptance of the NDA for filing means FDA has determined that the application is sufficiently complete to permit a substantive review. Under the Prescription Drug User Fee Act, the FDA's goal under standard review is to review and act on the NDA by December 27.

Actavis' progestin-only patch is designed to provide continuous delivery of norethindrone to the systemic circulation during a once-weekly, seven-day dosing regimen.

Actavis said that once-weekly dosing with the patch may improve compliance and convenience in progestin-only contraceptive users, as well as provide more consistent average plasma norethindrone levels than oral progestin-only products.

The NDA includes data from a 12-month, multicenter, open-label clinical trial conducted in the U.S. Actavis submitted the NDA to the FDA on February 26.

The stock is down 2.5 percent in pre-market activity at $117.

Click here to receive FREE breaking news email alerts for Actavis Plc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Justin Moore has been named Humanitarian of the Year by by the Armed Forces Foundation. Moore received the award alongside Big Machine Label Group President/CEO Scott Borchetta for their service and commitment to the morale and welfare of military families through the Crown Royal "Your Hero's Name Here" contest. International Business Machines Corp. said Wednesday after the markets closed that its first quarter profit fell 21% from last year, hurt by lower revenue as well as a hefty workforce rebalancing charge. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Stocks moved sharply higher over the course of the trading day on Wednesday, further offsetting the steep losses posted late last week. The markets benefited from a positive reaction to the latest earnings news as well as remarks by Federal Reserve Chairman Janet Yellen. The major averages saw further upside going into the close, ending the session at their best levels of the day.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.